Becoming a father seems to make a man less likely to die young. What’s more, when a father passes away within the first five years of his child’s life, the cause is usually non-natural and thus preventable.
Researchers tracked real-world data from 600 TAVR patients, following each one for approximately five years. Survival rates were similar for men and women early on, but then women started experiencing better outcomes after three years.
Using a DCB that releases sirolimus over an extended period of time appears to be both safe and effective when treating patients who present with NSTEMI or unstable angina.
The popular drugs, originally developed to treat diabetes, were also associated with an improved survival rate. Benefits were seen in patients who did and did not lose significant weight as a result of treatment.
Published in Clinical Imaging, the responses indicate that Trump administration policies have made it more difficult to acquire funding and collaborate with other researchers.
Gregg Stone, MD, discussing the value of IVUS and OCT over angiography to guide PCI procedures and actually improve outcomes based on a 12,000 patient meta analysis presented at ESC 2023.
NCDR report finds hospitals are seeing improvements but are still struggling to reach pre-COVID treatment thresholds years after pandemic precautions upended longstanding processes.
“Given the dramatic difference in death risk for older adults receiving complex PCI, we suggest that such interventions in this exceptionally vulnerable population should be approached with additional caution," researchers wrote.
The FDA is expected to base its decision in part on the STELLAR clinical trial, which included 163 adult patients treated with subcutaneous sotatercept and 160 patients treated with a placebo.
The popular SGLT2 inhibitor, sold by Boehringer Ingelheim and Eli Lilly and Company under the name Jardiance, has already been approved by the FDA to treat type 2 diabetes and heart failure.
